Orexo AB (publ)
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nikolaj Sørensen
- Full Time Employees
- 74
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Virdings allé 22 Uppsala UP Sweden 3002
- IPO Date
- Mar 15, 2018
- Website
- orexo.com
- Similar Companies
- Business
- Orexo AB (publ) is a Swedish specialty pharmaceutical company that develops and commercializes innovative drug formulations using proprietary drug delivery technologies, including the AmorphOX powder-based platform, for unmet medical needs in areas such as opioid use disorder, breakthrough cancer pain, insomnia and emergency rescue treatments; its core products include Zubsolv, a sublingual buprenorphine/naloxone treatment for opioid use disorder commercialized directly in the US, Izipry (formerly OX124), a high-dose intranasal naloxone rescue medication for opioid overdose now ready for commercial manufacturing and protected by patents until 2039, digital mental health programs for opioid use disorder and alcohol misuse via the Broca platform, as well as partnered developments like OX640, an intranasal epinephrine rescue medication for anaphylaxis using AmorphOX, OX125 for opioid overdose and OX390 in the pipeline. Founded in 1995 and headquartered in Uppsala, Sweden, with a US office in Morristown, New Jersey, the company operates primarily in the United States for opioid-related products through a dedicated sales force targeting high-prevalence states, while collaborating with global partners for commercialization in other therapeutic areas including vaccines and endometriosis via candidates like OXMPI, which it recently converted to shares in partner Gesynta Pharma valued at SEK 19 million. Recent developments include the successful issuance and oversubscription of SEK 500 million senior secured callable floating rate social bonds in March 2024 to refinance existing debt, attracting international institutional investors and supporting the impending US launch of Izipry alongside continued Zubsolv promotion; the company also reported 2024 net sales of SEK 590 million, reaffirmed a positive EBITDA outlook for 2025, advanced AmorphOX applications for vaccine stabilization and strengthened R&D with a move to new facilities.
Orexo AB (publ) (ORXOY) Q2 2026 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript
Invitation & Agenda: Orexo R&D Day on March 24
Invitation & Agenda: Orexo R&D Day on March 24
Orexo changes the organizational structure and management team to increase focus on development of new products
Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
Orexo to present clinical data for OX640 at the EAACI Congress
Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
Orexo initiates new study of OX640 in participants with allergic rhinitis
Orexo´s Nomination Committee for the Annual General Meeting 2025
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
Orexo: invitation to presentation of the Q2 2024 Interim Report
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm